{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:46:17Z","timestamp":1775245577646,"version":"3.50.1"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Craniopharyngiomas are rare intracranial tumors originating from the Rathke\u2019s pouch, affecting the sellar and parasellar regions. Despite their benign nature, they cause significant morbidity and mortality due to their proximity to vital structures such as the optic pathways and the hypothalamic-pituitary axis, resulting in endocrine, visual, neurological impairment, and hypothalamic syndrome. Classified into adamantinomatous (ACP) and papillary (PCP), these tumors differ in epidemiology, histology, and pathophysiology. ACP, the most common type, presents a bimodal peak incidence between 5 and 15 years of age and 45 and 60 years of age, while PCP is more restricted to adults. Traditional treatments such as surgery and radiotherapy face significant challenges, including high recurrence rates. Intracystic chemotherapy is used in monocystic ACP but with limited efficacy and adverse effects related to toxicity. Recent advances in molecular biology have introduced targeted therapies, such as BRAF and MEK inhibitors, which show potential benefits in craniopharyngioma patients, particularly in the PCP. For ACP, however, therapeutic outcomes remain limited despite advances in molecular understanding, including mutations in the <jats:italic>CTNNB1<\/jats:italic> gene and growth factors. Increasing investigation into the inflammatory microenvironment and immune response of these tumors presents new therapeutic possibilities and promising alternatives for tumor control, such as the use of anti-IL-6R, anti-VEGF agents and immune checkpoints inhibitors. This review aims to synthesize advancements in the pathophysiology of craniopharyngiomas and explore emerging therapeutic implications, focusing on precision medicine approaches for the management of this challenging disease.<\/jats:p>","DOI":"10.3389\/fendo.2025.1562942","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:10:21Z","timestamp":1747109421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches"],"prefix":"10.3389","volume":"16","author":[{"given":"Clariano","family":"Pires de Oliveira Neto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilvan Cort\u00eas","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina da Silva Pereira","family":"Damianse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel dos Santos","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"5","author":"M\u00fcller","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32112","article-title":"Craniopharyngioma: A comprehensive review of the clinical presentation, radiological findings, management, and future Perspective","volume":"10","author":"Alboqami","year":"2024","journal-title":"Heliyo"},{"key":"B3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-031-23705-8_11","article-title":"Craniopharyngioma in pediatrics and adults","volume":"1405","author":"Piloni","year":"2023","journal-title":"Adv Exp Med Bio"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Onco"},{"key":"B5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-021-03906-4","article-title":"Update on management of craniopharyngiomas","volume":"156","author":"Henderson","year":"2022","journal-title":"J Neuroonco"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0174","article-title":"Consequences of craniopharyngioma surgery in children","volume":"96","author":"M\u00fcller","year":"2011","journal-title":"J Clin Endocrinol Meta"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2024.04.177","article-title":"Long-term outcomes of surgery and radiation treatment for adult patients with craniopharyngioma","volume":"187","author":"Poiset","year":"2024","journal-title":"World Neurosur"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2022.28","article-title":"Is postoperative radiotherapy needed in the management of adult craniopharyngiomas","volume":"50","author":"Khriguian","year":"2023","journal-title":"Can J Neurol Sc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05001-4","article-title":"The spectrum of radiation therapy options for craniopharyngioma: a systematic review","author":"Harary","year":"2025","journal-title":"J Neuroonco"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-03983-z","article-title":"Disease control after radiotherapy for adult craniopharyngioma: Clinical outcomes from a large single-institution series","volume":"157","author":"Rutenberg","year":"2022","journal-title":"J Neuroonco"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04677-5","article-title":"Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review","volume":"36","author":"Whelan","year":"2020","journal-title":"Childs Nerv Sys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf030","article-title":"Molecular subtypes of adamantinomatous craniopharyngiomas","author":"An","year":"2025","journal-title":"Neuro Onco"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111068","article-title":"Deciphering craniopharyngioma subtypes: Single-cell analysis of tumor microenvironment and immune networks","volume":"27","author":"Matsuda","year":"2024","journal-title":"iScienc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2704136","article-title":"Targeted therapy in the management of modern craniopharyngiomas","volume":"27","author":"Reyes","year":"2022","journal-title":"Front Biosci (Landmark Ed"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult Papillary Craniopharyngiomas: A new treatment paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front Endocrinol (Lausanne"},{"key":"B16","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/2019.10.FOCUS19705","article-title":"Adamantinomatous craniopharyngioma: moving toward targeted therapies","volume":"48","author":"Hengartner","year":"2020","journal-title":"Neurosurg Focu"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.12688\/f1000research.11549.1","article-title":"Recent advances in molecular pathology of craniopharyngioma","volume":"6","author":"Larkin","year":"2017","journal-title":"F1000Re"},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ecl.2007.10.012","article-title":"Craniopharyngiomas","volume":"37","author":"Karavitaki","year":"2008","journal-title":"Endocrinol Metab Clin North A"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13030515","article-title":"Current advances in papillary craniopharyngioma: State-of-the-art therapies and overview of the literature","volume":"13","author":"Jannelli","year":"2023","journal-title":"Brain Sc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11102-012-0418-4","article-title":"Pathology and pathogenesis of craniopharyngiomas","volume":"16","author":"Larkin","year":"2013","journal-title":"Pituitar"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0957","article-title":"ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma","volume":"174","author":"Brastianos","year":"2016","journal-title":"Eur J Endocrino"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Gene"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1242\/dev.150490","article-title":"MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma","volume":"144","author":"Haston","year":"2017","journal-title":"Developmen"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","article-title":"Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles","volume":"4","author":"H\u00f6lsken","year":"2016","journal-title":"Acta Neuropathol Commu"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cance"},{"key":"B26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-025-06149-3","article-title":"Cell signaling communication within papillary craniopharyngioma revealed by an integrated analysis of single-cell RNA sequencing and bulk RNA sequencing","volume":"23","author":"Zhu","year":"2025","journal-title":"J Transl Me"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae091","article-title":"BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study","volume":"191","author":"De Alcubierre","year":"2024","journal-title":"Eur J Endocrino"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203479","article-title":"Update on neoadjuvant and adjuvant BRAF inhibitors in papillary craniopharyngioma: A systematic review","volume":"16","author":"Cossu","year":"2024","journal-title":"Cancers (Basel"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J Natl Cancer Ins"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF\u2013MEK inhibition in newly diagnosed papillary Craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"New Engl J Medicin"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.652005","article-title":"Dramatic therapeutic response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: A case report and literature review","volume":"8","author":"Fasano","year":"2021","journal-title":"Front Med (Lausann"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01127-6","article-title":"Descriptive epidemiology of craniopharyngiomas in the United States","volume":"24","author":"Momin","year":"2021","journal-title":"Pituitar"},{"key":"B33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-020-00939-0","article-title":"Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets","volume":"8","author":"Prince","year":"2020","journal-title":"Acta Neuropathol Commu"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197604)37:4<1944::aid-cncr2820370446>3.0.co","article-title":"Craniopharyngiomas: a clinical and pathological review","volume":"37","author":"Petito","year":"1976","journal-title":"Cance"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-005-1190-9","article-title":"The pathogenesis of craniopharyngiomas","volume":"21","author":"Prabhu","year":"2005","journal-title":"Childs Nerv Sys"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-14-0934","article-title":"Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas","volume":"172","author":"Gomes","year":"2015","journal-title":"Eur J Endocrino"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1101553108","article-title":"Increased Wingless (Wnt) signaling in pituitary progenitor\/stem cells gives rise to pituitary tumors in mice and humans","volume":"108","author":"Gaston-Massuet","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0538","article-title":"SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma","volume":"26","author":"Carreno","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-3-030-11339-1_3","article-title":"Adamantinomatous craniopharyngioma: genomics, radiologic findings, clinical, and prognosis","author":"M\u00fcller","year":"2019","journal-title":"Contemp Endocrinology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2187","article-title":"Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET\/GFRA3 receptors","volume":"97","author":"Garcia-Lavandeira","year":"2012","journal-title":"J Clin Endocrinol Meta"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1007\/s12672-010-0041-7","article-title":"CTNNB1 gene mutations, pituitary transcription factors, and microRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas","volume":"1","author":"Campanini","year":"2010","journal-title":"Horm Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12022-014-9341-8","article-title":"The wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis","volume":"26","author":"Preda","year":"2015","journal-title":"Endocr Patho"},{"key":"B43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s0092-8674(01)00330-0","article-title":"The structure of the beta-catenin\/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin","volume":"105","author":"Huber","year":"2001","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12613","article-title":"CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma","volume":"46","author":"Apps","year":"2020","journal-title":"Neuropathol Appl Neurobio"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0957-9","article-title":"Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma","volume":"124","author":"Andoniadou","year":"2012","journal-title":"Acta Neuropathol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12226","article-title":"Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma","volume":"41","author":"Martinez-Barbera","year":"2015","journal-title":"Neuropathol Appl Neurobio"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-005-1004-x","article-title":"Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region","volume":"109","author":"Buslei","year":"2005","journal-title":"Acta Neuropathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0890-6","article-title":"Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview","volume":"21","author":"Prieto","year":"2018","journal-title":"Pituitary"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2015.10.002","article-title":"Aberrant membranous expression of \u03b2-catenin predicts poor prognosis in patients with craniopharyngioma","volume":"19","author":"Li","year":"2015","journal-title":"Ann Diagn Patho"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2811","article-title":"EGFR signaling regulates tumor cell migration in craniopharyngiomas","volume":"17","author":"H\u00f6lsken","year":"2011","journal-title":"Clin Cancer Re"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not195","article-title":"Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth","volume":"16","author":"Stache","year":"2014","journal-title":"Neuro Onco"},{"key":"B53","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00428-009-0873-0","article-title":"A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas","volume":"456","author":"Burghaus","year":"2010","journal-title":"Virchows Archiv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ph17070949","article-title":"Why is Wnt\/\u03b2-catenin not yet targeted in routine cancer care","volume":"17","author":"de Pellegars-Malhortie","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020723","article-title":"Advancing craniopharyngioma management: A systematic review of current targeted therapies and future perspectives","volume":"25","author":"Agosti","year":"2024","journal-title":"Int J Mol Sc"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.3171\/jns.2000.92.2.0255","article-title":"Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas","volume":"92","author":"Jakacki","year":"2000","journal-title":"J Neurosurg"},{"key":"B57","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3171\/2012.9.PEDS12225","article-title":"Pegylated interferon-\u03b1-2b for children with recurrent craniopharyngioma","volume":"10","author":"Yeung","year":"2012","journal-title":"J Neurosurg Pediat"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa119","article-title":"Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report","volume":"22","author":"Goldman","year":"2020","journal-title":"Neuro Onco"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1225734","article-title":"Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report","volume":"14","author":"de Vos-Kerkhof","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00791","article-title":"Targeting IL-6 is a potential treatment for primary cystic craniopharyngioma","volume":"9","author":"Grob","year":"2019","journal-title":"Front Onco"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2023.10.003","article-title":"First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: Case report and illustrative review","volume":"84","author":"De Rosa","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28753","article-title":"Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc8933","article-title":"Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma","volume":"9","author":"Jiang","year":"2023","journal-title":"Sci Ad"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216905","article-title":"Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: Based on single nucleus RNA-seq and spatial transcriptome profiling","volume":"592","author":"Chen","year":"2024","journal-title":"Cancer Let"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae015","article-title":"Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis","volume":"26","author":"Prince","year":"2024","journal-title":"Neuro Onco"},{"key":"B66","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41419-024-06840-1","article-title":"Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization","volume":"15","author":"Xu","year":"2024","journal-title":"Cell Death Di"},{"key":"B67","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13578-024-01299-1","article-title":"Single-cell and spatial sequencing identifies senescent and germinal tumor cells in adamantinomatous craniopharyngiomas","volume":"14","author":"Wang","year":"2024","journal-title":"Cell Biosc"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-020-1013-4","article-title":"Clinical features and prognosis of pediatric infradiaphragmatic craniopharyngioma relative to the tumor inflammatory response","volume":"89","author":"Peng","year":"2021","journal-title":"Pediatr Re"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlx061","article-title":"Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma","volume":"76","author":"Donson","year":"2017","journal-title":"J Neuropathol Exp Neuro"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00563","article-title":"Immunological approaches towards cancer and inflammation: A cross talk","volume":"9","author":"Qu","year":"2018","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6538","article-title":"Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration","volume":"15","author":"Zhou","year":"2017","journal-title":"Mol Med Re"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol The"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/979748","article-title":"Cytokine patterns in brain tumour progression","volume":"2013","author":"Albulescu","year":"2013","journal-title":"Mediators Inflam"},{"key":"B74","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target The"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10281","article-title":"Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome","volume":"94","author":"Vidal","year":"2002","journal-title":"Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1999.91.5.0831","article-title":"Expression of vascular permeability factor in craniopharyngioma","volume":"91","author":"Vaquero","year":"1999","journal-title":"J Neurosurg"},{"key":"B77","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1074\/jbc.M112.417451","article-title":"Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells","volume":"288","author":"Mazor","year":"2013","journal-title":"J Biol Che"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.362","article-title":"Dual roles of tumour cells-derived matrix metalloproteinase 2 on brain tumour growth and invasion","volume":"117","author":"Yu","year":"2017","journal-title":"Br J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1481050","article-title":"The expression of VDACs and Bcl2 family genes in pituitary adenomas: clinical correlations and postsurgical outcomes","volume":"15","author":"Facundo","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20871","article-title":"Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1","volume":"115","author":"Loeffler","year":"2005","journal-title":"Int J Cancer J Int du cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2776-x","article-title":"The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study","volume":"138","author":"Chen","year":"2018","journal-title":"J Neurooncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995655","article-title":"Immune infiltration in aggressive papillary craniopharyngioma: High infiltration but low action","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immuno"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28253","article-title":"CXCL12\/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K\/AKT signal pathway","volume":"120","author":"Yin","year":"2019","journal-title":"J Cell Bioche"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-140397","article-title":"High expression levels of CXCL12 and CXCR4 predict recurrence of adamantinomatous craniopharyngiomas in children","volume":"14","author":"Gong","year":"2014","journal-title":"Cancer Biomarkers"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.10.020","article-title":"Chemokines as mediators of tumor angiogenesis and neovascularization","volume":"317","author":"Keeley","year":"2011","journal-title":"Exp Cell Re"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00378.2019","article-title":"The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment","volume":"318","author":"Bikfalvi","year":"2020","journal-title":"Am J Physiol Cell Physio"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2174\/0929867329666220819115849","article-title":"Immune checkpoint inhibitors: Recent clinical advances and future prospects","volume":"30","author":"Banday","year":"2023","journal-title":"Curr Med Che"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105490","article-title":"Immunomodulatory precision: A narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment","volume":"25","author":"Qiu","year":"2024","journal-title":"Int J Mol Sc"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Me"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Me"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlw116","article-title":"Genomic alterations of adamantinomatous and papillary craniopharyngioma","volume":"76","author":"Goschzik","year":"2017","journal-title":"J Neuropathol Exp Neuro"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2267","article-title":"Concise review: Paracrine role of stem cells in pituitary tumors: A focus on adamantinomatous craniopharyngioma","volume":"34","author":"Martinez-Barbera","year":"2016","journal-title":"Stem Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro Onco"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Me"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04899-6","article-title":"Current clinical trials for craniopharyngiomas: what\u2019s on the horizon","volume":"172","author":"Joshi","year":"2025","journal-title":"J Neuroonco"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox056","article-title":"Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN","volume":"19","author":"Kilday","year":"2017","journal-title":"Neuro Onco"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1562942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:10:22Z","timestamp":1747109422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1562942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":97,"alternative-id":["10.3389\/fendo.2025.1562942"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1562942","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1562942"}}